ClinicalTrials.gg
CompletedNCT07588139Updated Oct 9, 2026

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

A Phase 1 interventional study of Povorcitinib and Ruxolitinib in Healthy Participants, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • INCB054707
03

In context

Lead sponsor

Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.

Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Aged 18 to 65 years, inclusive, at the time of signing the ICF.
  • between 18.0 and 30.5 kg/m2, inclusive.
  • No findings on screening evaluations (clinical, laboratory, and ).
  • Ability to swallow and retain oral medication.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
  • Participants with any history of an disease diagnosis.
  • History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension.
  • History or presence of an abnormal .
  • Presence or history of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn's disease or chronic pancreatitis).
  • Any or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
  • Current or recent (within 3 months of screening) gastrointestinal disease or surgery (including cholecystectomy; excluding appendectomy and hernia repair) that could affect the absorption of study drug.
  • Any major surgery within 4 weeks of screening.
  • Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for plasma-only donation).
  • Blood transfusion within 4 months of check-in (Day -1).
  • Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment (includes latent treated tuberculosis).
  • Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof.
  • Positive test for , , or . Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
  • Has received a (including attenuated) or anticipation of need for such a vaccine during the study within 3 months prior to the first dose of study drug. Note: Examples of live vaccines include but are not limited to the following: measles, mumps, rubella, chickenpox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid. Seasonal influenza vaccines for injection are generally killed-virus vaccines and are allowed; however, intranasal influenza vaccines are live, attenuated vaccines and are not allowed.
  • Medical or self-reported history of alcoholism within 3 months of screening.
  • History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption > 21 units per week for males and > 14 units for females (1 unit = 8 oz of beer or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
  • Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study treatment with another medication or current enrollment in another investigational drug study.
  • Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose/application of study treatment with strong inducers or strong and moderate inhibitors of , P-gp, or BCRP (refer to the Drug Interaction Database for prohibited drugs.
  • Consumption of red wine, Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of study drug.
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
  • Known or severe reaction to povorcitinib or any of povorcitinib, to ruxolitinib or any excipients of ruxolitinib or any JAK inhibitors.
  • Inability to undergo venipuncture or tolerate venous access.
  • History of tobacco or nicotine containing product use within 1 month of screening.
  • Use of prescription drugs (including hormonal ) within 14 days of study treatment administration/application or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days before study treatment administration/application. However, occasional and standard dose paracetamol, acetaminophen, ibuprofen, and standard dose vitamins are permitted. Mega dose vitamins or supplements are not permissible.
  • Women who are pregnant or breastfeeding.
  • Any condition that would interfere with full participation in the study, including administration/application of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Excessive exercise (ie Iron man®, triathlon, etc) within 7 days before check-in (Day -1).
  • Tattoo or scarring at skin sample sites.
  • Participants prone to keloid or hypertrophic scar formation or any known wound healing disorder.
  • Not willing to avoid excessive sun exposure, steam baths, sauna, swimming, and other strenuous activities for 14 days after Day 12 to ensure good tissue regeneration.
  • Pronounced hairiness on the planned application sites, dOFM probe insertion sites, and skin collection sites, that may negatively affect dose application, probe placement, and/or sample testing.
  • Not willing to refrain from shaving the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, or using skin care products on the planned application sites, dOFM probe insertion sites, and skin biopsy collection sites, for at least 5 days before Day 1.
  • Not willing to avoid sunbathing, using tanning salons, or using spray/lotion tanning agents within 7 days prior to Day 1 dose administration/application.
  • Presence of needle phobia.
  • Increased risk of thrombosis (eg, personal or first-degree relative[s] history of deep vein thrombosis).

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1: Ruxolitinib 1.5 % Cream

    Ruxolitinib cream applied topically twice daily.

    Drug: Ruxolitinib

  • Experimental
    Cohort 2: Povorcitinib

    Povorcitinib will be administered at the protocol defined dose.

    Drug: Povorcitinib

  • Experimental
    Cohort 3: Povorcitinib

    Povorcitinib will be administered at the protocol defined dose.

    Drug: Povorcitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib

    Defined as the maximum observed plasma concentration.

    Time frame: Up to Day 12

  2. Pharmacokinetics Parameter: AUClast of dISF ruxolitinib

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

    Time frame: Up to Day 12

  3. Pharmacokinetics Parameter: AUC∞ of dISF ruxolitinib

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

    Time frame: Up to Day 12

  4. Pharmacokinetics Parameter: Cmax of dISF povorcitinib

    Defined as the maximum observed plasma concentration.

    Time frame: Up to Day 12

  5. Pharmacokinetics Parameter: AUClast of dISF povorcitinib

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

    Time frame: Up to Day 12

  6. Pharmacokinetics Parameter: AUC∞ of dISF povorcitinib

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

    Time frame: Up to Day 12

  7. Pharmacokinetics Parameter: Cmax of plasma ruxolitinib

    Defined as the maximum observed plasma concentration.

    Time frame: Up to Day 12

  8. Pharmacokinetics Parameter: AUClast of plasma ruxolitinib

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

    Time frame: Up to Day 12

  9. Pharmacokinetics Parameter: AUC∞ of plasma ruxolitinib

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

    Time frame: Up to Day 12

  10. Pharmacokinetics Parameter: Cmax of plasma povorcitinib

    Defined as the maximum observed plasma concentration.

    Time frame: Up to Day 12

  11. Pharmacokinetics Parameter: AUClast of plasma povorcitinib

    Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.

    Time frame: Up to Day 12

  12. Pharmacokinetics Parameter: AUC∞ of plasma povorcitinib

    Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.

    Time frame: Up to Day 12

Secondary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as any adverse event, either reported for the first time or the worsening of a pre-existing event, occurring after first dose of study treatment.

    Time frame: Up to Day 28

  2. Pharmacokinetics Parameter: tmax of dISF ruxolitinib

    Defined as the time to maximum concentration.

    Time frame: Up to Day 12

  3. Pharmacokinetics Parameter: t½ of dISF ruxolitinib

    Defined as the apparent terminal-phase disposition half-life.

    Time frame: Up to Day 12

  4. Pharmacokinetics Parameter: CL/F of dISF ruxolitinib

    Defined as the apparent clearance.

    Time frame: Up to Day 12

  5. Pharmacokinetics Parameter: Vz/F of dISF ruxolitinib

    Defined as the apparent volume of distribution.

    Time frame: Up to Day 12

  6. Pharmacokinetics Parameter: λz of dISF ruxolitinib

    Defined as the terminal-phase disposition rate constant.

    Time frame: Up to Day 12

  7. Pharmacokinetics Parameter: tmax of dISF povorcitinib

    Defined as the time to maximum concentration.

    Time frame: Up to Day 12

  8. Pharmacokinetics Parameter: t½ of dISF povorcitinib

    Defined as the apparent terminal-phase disposition half-life.

    Time frame: Up to Day 12

  9. Pharmacokinetics Parameter: CL/F of dISF povorcitinib

    Defined as the apparent clearance.

    Time frame: Up to Day 12

  10. Pharmacokinetics Parameter: Vz/F of dISF povorcitinib

    Defined as the apparent volume of distribution.

    Time frame: Up to Day 12

  11. Pharmacokinetics Parameter: λz of dISF povorcitinib

    Defined as the terminal-phase disposition rate constant.

    Time frame: Up to Day 12

  12. Pharmacokinetics Parameter: tmax of plasma ruxolitinib

    Defined as the time to maximum concentration.

    Time frame: Up to Day 12

  13. Pharmacokinetics Parameter: t½ of plasma ruxolitinib

    Defined as the apparent terminal-phase disposition half-life.

    Time frame: Up to Day 12

  14. Pharmacokinetics Parameter: CL/F of plasma ruxolitinib

    Defined as the apparent clearance.

    Time frame: Up to Day 12

  15. Pharmacokinetics Parameter: Vz/F of plasma ruxolitinib

    Defined as the apparent volume of distribution.

    Time frame: Up to Day 12

  16. Pharmacokinetics Parameter: λz of plasma ruxolitinib

    Defined as the terminal-phase disposition rate constant.

    Time frame: Up to Day 12

  17. Pharmacokinetics Parameter: tmax of plasma povorcitinib

    Defined as the time to maximum concentration.

    Time frame: Up to Day 12

  18. Pharmacokinetics Parameter: t½ of plasma povorcitinib

    Defined as the apparent terminal-phase disposition half-life.

    Time frame: Up to Day 12

  19. Pharmacokinetics Parameter: CL/F of plasma povorcitinib

    Defined as the apparent clearance.

    Time frame: Up to Day 12

  20. Pharmacokinetics Parameter: Vz/F of plasma povorcitinib

    Defined as the apparent volume of distribution.

    Time frame: Up to Day 12

  21. Pharmacokinetics Parameter: λz of plasma povorcitinib

    Defined as the terminal-phase disposition rate constant.

    Time frame: Up to Day 12

07

Study locations

1 site
  • Axis Clinicals
    Dilworth, Minnesota 56529, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2026 to primary completion in Sep 2026, 3 months.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
May 18, 2026
Primary completionActual
Sep 8, 2026
CompletionActual
Oct 5, 2026was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 9, 2026
Primary completion
Sep 3, 2026→Sep 8, 2026 (actual)
Oct 9, 2026
Study completion
Sep 19, 2026→Oct 5, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Completed
    Primary completion Sep 3, 2026→Sep 8, 2026 (now actual)
    Study completion Sep 19, 2026→Oct 5, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07588139
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 14, 2026
Start date
May 18, 2026
Primary completion
Sep 8, 2026
Completion
Oct 5, 2026
Last update
Oct 9, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Povorcitinib · Ruxolitinib

Start the discussion